MIM
IMVT icon

Monashee Investment Management’s Immunovant IMVT Stock Holding History

Monashee Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$3.23M – 103
2024
Q1 		$3.23M Buy
100,000
+30,000
+43% +$1.09M 0.38% 48
2023
Q4 		$2.95M Sell
70,000
-100,000
-59% -$3.68M 0.52% 20
2023
Q3 		$6.53M Buy
+170,000
New +$3.84M 2.73% 6
2020
Q4 		– Sell
-50,000
Closed -$1.76M – 301
2020
Q3 		$1.76M Buy
+50,000
New +$1.5M 0.38% 70

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Monashee Investment Management's IMVT Position: Q2 2024 in Review

Monashee Investment Management sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 100,000 shares — an estimated $3.23M sold.

Monashee Investment Management first reported a position in IMVT in Q3 2020 and held it in 4 quarters. The position peaked at $6.53M in Q3 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Monashee Investment Management reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Monashee Investment Management sold 100,000 Immunovant shares in Q2 2024, an estimated $3.23M.
  • Monashee Investment Management first reported a position in Immunovant in Q3 2020 and held it in 4 quarters.
  • Monashee Investment Management's Immunovant position peaked at $6.53M in Q3 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Monashee Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.